Ind-Swift Laboratories (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Ind-Swift Laboratories Limited |
|||
|
Price: ₹112.19 (+0.39%) | ||
| 52 Week Low: ₹68.72 52 Week High: ₹186.00 |
|||
| Market Capital: 626.61 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Ind-Swift Laboratories Stock Comparison: Ind-Swift Laboratories vs Kilitch Drugs | Ind-Swift Laboratories vs Wanbury | Ind-Swift Laboratories vs Nectar Lifesciences | Ind-Swift Laboratories vs Valiant Laboratories | Ind-Swift Laboratories vs Sakar Healthcare | Ind-Swift Laboratories vs Medicamen Biotech |
|||
Share Price HistoryINDSWFTLAB FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusNo Split
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Ind-Swift Laboratories Share Price Target For 2025
- 1.1.1: Ind-Swift Laboratories Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Ind-Swift Laboratories Share Price Target For 2026
- 1.2.1: Ind-Swift Laboratories Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Ind-Swift Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Ind-Swift Laboratories Brief Company Overview
- 4: Ind-Swift Laboratories Financial Performance
- 4.0.1: Is Ind-Swift Laboratories A Good Buy For Long Term?
Ind-Swift Laboratories, a Small Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 187.7% returns in 5-year with 40.3% profit margin, making it a potential Multibagger.
To predict the Ind-Swift Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Ind-Swift Laboratories Share Price Target For 2025
The line chart displays the monthly closing prices of Ind-Swift Laboratories with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Ind-Swift Laboratories shares in 2025, see the table below.
Ind-Swift Laboratories Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 124.3 (+10.79%) | Price Action: Jul 2024 Low |
| 2025 Target 2 | 122.9 (+9.53%) | Price Action: Feb 2024 High |
| 2025 Target 1 | 119.91 (+6.88%) | Price Action: Nov 2024 High |
| Current Price | 112.19 | Ind-Swift Laboratories's share price as of 01 Jul 2025 |
| Stop Loss 1 | 108.25 (-3.52%) | Price Action: 25 Jun 2025 Low |
| Stop Loss 2 | 106.84 (-4.76%) | Price Action: 06 Feb 2025 High |
| Stop Loss 3 | 105.75 (-5.75%) | Price Action: Dec 2023 High |
Short-Term Technical Outlook
Current Technical Position: Ind-Swift Laboratories is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹100.26 serves as the nearest technical reference point.
Historical Returns: 3-month: +12.21% | 6-month: -13.23% | 1-year: -27.49%
Ind-Swift Laboratories Share Price Target For 2026
The line chart displays the monthly closing prices of Ind-Swift Laboratories with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Ind-Swift Laboratories shares in 2026, see the table below.
Ind-Swift Laboratories Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 191.89 (+71.04%) | Price Action: Chart |
| 2026 Target 2 | 188.31 (+67.84%) | Fibonacci Extension Level 64.90% |
| 2026 Target 1 | 186.0 (+65.79%) | Fibonacci Extension Level 100.00% |
| Current Price | 112.19 | Ind-Swift Laboratories's share price as of 01 Jul 2025 |
| Stop Loss 1 | 94.74 (-15.56%) | Price Action: 19 Feb 2025 High |
| Stop Loss 2 | 93.68 (-16.5%) | Price Action: 24 Feb 2025 High |
| Stop Loss 3 | 92.63 (-17.44%) | Price Action: 21 Mar 2025 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Ind-Swift Laboratories is currently trading at 37.1% of its 52-week range (₹68.72 - ₹186).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: -27.49% | 3-year: +59.81% | 5-year: +187.66%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Ind-Swift Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹112.19 | ||
| 2025 | ₹136.06 | +21.27% | ₹138.10 |
| 2026 | ₹175.45 | +28.95% | ₹178.08 |
| 2027 | ₹205.20 | +16.95% | ₹208.28 |
| 2028 | ₹256.28 | +24.89% | ₹260.12 |
| 2029 | ₹307.91 | +20.14% | ₹312.53 |
| 2030 | ₹400.84 | +30.18% | ₹406.85 |
| 2031 | ₹495.89 | +23.71% | ₹503.33 |
| 2032 | ₹607.80 | +22.56% | ₹616.92 |
| 2033 | ₹715.29 | +17.68% | ₹726.02 |
| 2034 | ₹797.53 | +11.49% | ₹809.49 |
| 2035 | ₹907.70 | +13.81% | ₹921.32 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Ind-Swift Laboratories Brief Company Overview
Ind-Swift Laboratories Limited: A Leader in Pharmaceutical Manufacturing Established in 1995, Ind-Swift Laboratories Limited is a prominent player in India's pharmaceutical industry. The company specializes in developing, manufacturing, and distributing a diverse range of...
active pharmaceutical ingredients (APIs) and advanced intermediates. Ind-Swift's extensive product portfolio caters to various therapeutic areas, including cardiovascular, antihistaminic, antidiabetic, and Parkinson's disease. The company also provides reference standards, impurities, and contract research and manufacturing services. Its products are exported globally, and it maintains a strong market presence both domestically and internationally. Ind-Swift is known for its commitment to quality and innovation. The company adheres to stringent regulatory standards and has a dedicated team of scientists and researchers constantly exploring new advancements in the pharmaceutical field.Ind-Swift Laboratories Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 626.61 Crore | Market valuation of Ind-Swift Laboratories's shares. |
| Revenue (TTM) | 1,003.72 Crore | Total revenue generated by Ind-Swift Laboratories over the past twelve months. |
| Net Income (TTM) | +404.65 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -30.13% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +40.31% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-89.3% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-94.6% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
1.78 | Company's total debt divided by total shareholder equity. |
| Total Debt | 16.62 Crore | Sum of Ind-Swift Laboratories's current & long-term financial obligations. |
| Total Cash | 431.92 Crore | Total amount of liquid funds available to Ind-Swift Laboratories. |
| Beta | 0.26 | Beta is less than 1 indicating that the Ind-Swift Laboratories's price is less volatile than the market. |
Is Ind-Swift Laboratories A Good Buy For Long Term?
Ind-Swift Laboratories, a small-cap stock with a market capitalization of ₹626.61 crore, shows mixed signals. While it boasts a strong profit margin of 40.31% and substantial cash reserves (₹431.92 crore in Q1 2024-25), a significant drop in revenue (-89.3% QoQ) and earnings (-94.6% YoY) raises serious concerns. Despite impressive 3- and 5-year returns (61.68% and 106.88% respectively), the recent negative performance (-39.39% in the past 3 months) warrants caution. Therefore, considering the current volatile trend, it's currently not a good buy for the long term. Further investigation is needed.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
